Company intelligence / Profile preview
Toragen, Inc.
San Diego, California, United Statestoragen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead candidate TGN-S11 has entered a Phase I clinical trial in patients with relapsed or metastatic HPV-related cancers. Early results show no safety concerns across the first three dose cohorts; one-third of subjects experienced tumor size reduction and decreased circulating tumor HPV DNA. Combination studies with Keytruda are planned in the next phase.[1][2][5]
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (e.g., TGN-S11 and TGN-S15)[1][2]Immunotherapy (combination with checkpoint inhibitors like Keytruda)[1][5]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Collaboration with UC San Diego Moores Cancer Centercombination study planned with Merck’s Keytruda (pembrolizumab) but not a formal partnership disclosed yet.[4]
Beyond the preview
Go deeper on Toragen, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Toragen, Inc..